Mepolizumab initiation by day 30 and glucocorticoid exposure in newly diagnosed EGPA: a single-center 30-day landmark cohort study
Shota Kaburaki, Toru Tanaka, Koichiro Kamio, Yosuke Tanaka, Namiko Taniuchi, Kazuo Kasahara, Masahiro Seike · 2026
Read Mepolizumab initiation by day 30 and glucocorticoid exposure in newly diagnosed EGPA: a single-center 30-day landmark cohort study by Shota Kaburaki, Toru Tanaka, Koichiro Kamio, Yosuke Tanaka, Namiko Taniuchi, Kazuo Kasahara, Masahiro Seike (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13536814.txt.
Description
Shota Kaburaki and colleagues pilot a timing question for a targeted drug in a rare vessel inflammation disease in a 2026 single-center study. Thirty patients newly diagnosed with eosinophilic granulomatosis with polyangiitis started steroid treatment. The pilot compared patients who began mepolizumab, a drug that lowers steroid need, within thirty days against those who had not begun it by that point. Steroid exposure over the next year was the main measure.
Only six patients started the drug early, against twenty-one in the comparison group at the thirty-day mark. Later oral steroid totals ran much lower in the early group, as did daily doses at one year. Disease activity scores reached zero in both groups by three months. The authors stress the small, nonrandom design and call the findings early clues only.
Catalog record
| CREATOR | Shota Kaburaki, Toru Tanaka, Koichiro Kamio, Yosuke Tanaka, Namiko Taniuchi, Kazuo Kasahara, Masahiro Seike |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40777 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |